SPT Labtech has announced a strategic collaboration with Illumina to develop a novel automated sample preparation platform in genomics. 

The platform, designed to streamline and standardise genomics workflows across decentralised healthcare environments, will support laboratories using Illumina’s MiSeq i100 benchtop sequencing system. The system offers more accessible high-quality next-generation sequencing to labs around the world. 

The collaboration between SPT Labtech and Illumina aims to support improved patient care in oncology by enabling broader access to high-quality genomic characterisation of disease. By bringing advanced automation to laboratories of all sizes and settings, the collaboration could accelerate the delivery of actionable insights from sample to result. 

“This next phase of collaboration with Illumina reflects our shared focus on enabling efficient and accessible genomics workflows, further expanding SPT Labtech’s presence in the clinical genomics market,” said Rob Walton, Chief Executive Officer at SPT Labtech. 

“With the rapid global adoption of Illumina’s MiSeq i100 platform and the recent shipment of its 1,000th system, there is a growing demand from laboratories seeking to perform their sequencing operations in-house, thereby maximising control and reducing turnaround times.  

“By combining our expertise in automation and sequencing, we are well positioned to help laboratories adopt advanced genomics workflows within decentralised healthcare settings.” 

“Labs around the world rely on Illumina for high-quality, reliable insights and end-to-end workflows that make it easier for them to unlock crucial genomic insights faster,” added Todd Christian, Senior Vice President of Services, Arrays, and Genomic Access at Illumina. 

“This collaboration builds on that history and doubles down on our commitment to expand access to next-generation sequencing for labs of all sizes, ultimately enabling researchers and clinicians to drive breakthroughs that matter for the patients they serve.”